Tozadenant clinical trials
Also written SYN115.
How each study uses tozadenant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Biotie Therapies Inc. (7) · Virginia Commonwealth University (1)
Studies
Open first, then newest update. How each study uses tozadenant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- An fMRI Study of SYN115 in Cocaine Dependent SubjectsCompletedEarly Phase 1Virginia Commonwealth UniversityNCT00783276Written as SYN115How we know
- Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.TerminatedPhase 3Biotie Therapies Inc.NCT03051607Written as TozadenantHow we know
- Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's PatientsTerminatedPhase 3Biotie Therapies Inc.NCT02453386Written as tozadenantHow we know
- Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing OffCompletedPhase 2/3Biotie Therapies Inc.NCT01283594Written as Tozadenant (SYN115) 60 mg BIDHow we know
- A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug UsersTerminatedPhase 1Biotie Therapies Inc.NCT03200080Written as TozadenantHow we know
- Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of TozadenantTerminatedPhase 1Biotie Therapies Inc.NCT03212313Written as TozadenantHow we know
- Study to Evaluate SYN115 in Parkinson's DiseaseCompletedPhase 2Biotie Therapies Inc.NCT00605553Written as TozadenantHow we know
- Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled TozadenantCompletedPhase 1Biotie Therapies Inc.NCT02240290Written as tozadenant tabletHow we know
Codes
What other systems call tozadenant · ClinicalTrials.gg INT000119
- MeSH (NLM) C000593256tozadenantOne source NLM
- UNII (FDA) D9K857J81ITOZADENANTConfirmed FDA, NLM, Wikidata
- Wikidata Q27089009tozadenantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152704TozadenantOne source FDA
- DrugBank DB12203One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000593256 | tozadenant | One source NLM |
| UNII (FDA) | D9K857J81I | TOZADENANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27089009 | tozadenant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152704 | Tozadenant | One source FDA |
| DrugBank | DB12203 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.